Literature DB >> 9477070

Effects of intrathecally administered lamotrigine, a glutamate release inhibitor, on short- and long-term models of hyperalgesia in rats.

J G Klamt1.   

Abstract

BACKGROUND: Lamotrigine is a sodium channel blocker that inhibits the neuronal release of glutamate. Systemic administration of lamotrigine induces analgesia in short- and long-term models of hyperalgesia in rats. Considering the key role of N-methyl-D-aspartate receptors in the sensitization of dorsal horn neurons that leads to hyperalgesia, the author hypothesizes that intrathecally injected lamotrigine would be effective in reducing the hyperalgesia.
METHODS: Short-term hyperalgesia was induced by unilateral intraplantar injection of prostaglandin E2. Long-term hyperalgesia was produced by treating rats with streptozotocin, which causes diabetic neuropathy and, in a different group of animals, by loose ligation of the sciatic nerve (chronic constriction injury). Hyperalgesia was assessed by measuring withdrawal reaction time after paw pressure, and analgesia was measured by the thermal tail-flick test.
RESULTS: In the short-term model, intrathecally administered lamotrigine (12.5, 25.0, and 100.0 microg) produced a dose-dependent increase in the reaction time of the hyperalgesic paw. The highest dose that completely restored the reaction time to control levels (26-29 s) from the hyperalgesic levels (12-15 s) did not affect the reaction time of the normal contralateral paw. In the tail-flick test, a consistent effect could be observed only with doses of 200 microg, which caused transient motor impairment of the hind paws. In the long-term models of hyperalgesia, intrathecally administered lamotrigine produced a dose-dependent and long-lasting (24-48 h) antihyperalgesic effect.
CONCLUSIONS: Intrathecally administered lamotrigine produced a spinal, dose-dependent, and long-lasting antihyperalgesic effect in short- and long-term neuropathic models of hyperalgesia.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9477070     DOI: 10.1097/00000542-199802000-00028

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  6 in total

Review 1.  Glutamate receptors and nociception: implications for the drug treatment of pain.

Authors:  M E Fundytus
Journal:  CNS Drugs       Date:  2001-01       Impact factor: 5.749

2.  In vivo pharmacology of BIIR 561 CL, a novel combined antagonist of AMPA receptors and voltage-dependent Na(+) channels.

Authors:  M Wienrich; M Brenner; W Löscher; R Palluk; M Pieper; H Potschka; T Weiser
Journal:  Br J Pharmacol       Date:  2001-07       Impact factor: 8.739

Review 3.  Anticonvulsants for neuropathic pain syndromes: mechanisms of action and place in therapy.

Authors:  I W Tremont-Lukats; C Megeff; M M Backonja
Journal:  Drugs       Date:  2000-11       Impact factor: 9.546

4.  Gene transfer of GLT-1, a glial glutamate transporter, into the spinal cord by recombinant adenovirus attenuates inflammatory and neuropathic pain in rats.

Authors:  Sanae Maeda; Ai Kawamoto; Yumi Yatani; Hisashi Shirakawa; Takayuki Nakagawa; Shuji Kaneko
Journal:  Mol Pain       Date:  2008-12-24       Impact factor: 3.395

5.  Intrathecal lamotrigine attenuates antinociceptive morphine tolerance and suppresses spinal glial cell activation in morphine-tolerant rats.

Authors:  In-Gu Jun; Sung-Hoon Kim; Yang-In Yoon; Jong-Yeon Park
Journal:  J Korean Med Sci       Date:  2013-01-29       Impact factor: 2.153

6.  Intrathecal lamotrigine attenuates mechanical allodynia and suppresses microglial and astrocytic activation in a rat model of spinal nerve ligation.

Authors:  Yun-Sik Choi; In-Gu Jun; Sung-Hoon Kim; Jong-Yeon Park
Journal:  Yonsei Med J       Date:  2013-03-01       Impact factor: 2.759

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.